Diethyl 2-diazenyl-2-methyl-3-oxopentanedioate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Diethyl 2-diazenyl-2-methyl-3-oxopentanedioate
• 英文别名: diethyl 2-diazenyl-2-methyl-3-oxopentanedioate
• 化学式: C₁₀H₁₆N₂O₅
• 分子量: 244.24
• InChiKey: LLBQWXLSDXTTJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS PAR AMIDE, UTILES COMME MODULATEURS D'IL-12, IL-23 ET/OU DE RÉPONSES À L'IFN&Agr;
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014074661A1

  公开（公告）日：2014-05-15

  Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.

  具有以下化学式I的化合物，或其立体异构体或药用可接受的盐，其中R1、R2、R3、R4和R5如本文所定义，在通过作用于Tyk-2引起信号转导抑制的过程中，对IL-12、IL-23和/或IFNa的调节是有用的。
• AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150299183A1

  公开（公告）日：2015-10-22

  Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

  具有以下公式I的化合物，或其立体异构体或药学上可接受的盐，其中R1，R2，R3，R4和R5如本文所定义，可用于通过作用于Tyk-2来引起信号转导抑制，从而调节IL-12，IL-23和/或IFNα。
• PYRIDAZINE COMPOUNDS AS JAK INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20170174673A1

  公开（公告）日：2017-06-22

  In one aspect, the invention provides a compound according to formula I, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting Janus kinases (JAKs), and methods for treating a condition or disorder mediated at least in part by JAK kinase activity are also described.
• ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
  申请人：Galecto Biotech AB

  公开号：US20170349619A1

  公开（公告）日：2017-12-07

  An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
• US9505748B2
  申请人：——

  公开号：US9505748B2

  公开（公告）日：2016-11-29